RESUMO
BACKGROUND: Maternal-foetal transmission of Chagas disease (CD) affects newborns worldwide. Although Benznidazole and Nifurtimox therapies are the standard treatments, their use during pregnancy is contra-indicated. The effectiveness of trypanocidal medications in preventing congenital Chagas Disease (cCD) in the offsprings of women diagnosed with CD was highly suggested by other studies. METHODS: We performed a systematic review and meta-analysis of studies evaluating the effectiveness of treatment for CD in women of childbearing age and reporting frequencies of cCD in their children. PubMed, Scopus, Web of Science, Cochrane Library, and LILACS databases were systematically searched. Statistical analysis was performed using Rstudio 4.2 using DerSimonian and Laird random-effects models. Heterogeneity was examined with the Cochran Q test and I2 statistics. A p-value of <0.05 was considered statistically significant. RESULTS: Six studies were included, comprising 744 children, of whom 286 (38.4%) were born from women previously treated with Benznidazole or Nifurtimox, trypanocidal agents. The primary outcome of the proportion of children who were seropositive for cCD, confirmed by serology, was signigicantly lower among women who were previously treated with no congenital transmission registered (OR 0.05; 95% Cl 0.01-0.27; p = 0.000432; I2 = 0%). In women previously treated with trypanocidal drugs, the pooled prevalence of cCD was 0.0% (95% Cl 0-0.91%; I2 = 0%), our meta-analysis confirms the excellent effectiveness of this treatment. The prevalence of adverse events in women previously treated with antitrypanocidal therapies was 14.01% (95% CI 1.87-26.14%; I2 = 80%), Benznidazole had a higher incidence of side effects than Nifurtimox (76% vs 24%). CONCLUSION: The use of trypanocidal therapy in women at reproductive age with CD is an effective strategy for the prevention of cCD, with a complete elimination of congenital transmission of Trypanosoma cruzi in treated vs untreated infected women.
Assuntos
Doença de Chagas , Transmissão Vertical de Doenças Infecciosas , Nifurtimox , Nitroimidazóis , Tripanossomicidas , Humanos , Feminino , Tripanossomicidas/uso terapêutico , Tripanossomicidas/efeitos adversos , Doença de Chagas/tratamento farmacológico , Doença de Chagas/prevenção & controle , Doença de Chagas/congênito , Doença de Chagas/transmissão , Gravidez , Transmissão Vertical de Doenças Infecciosas/prevenção & controle , Nifurtimox/uso terapêutico , Nifurtimox/efeitos adversos , Nitroimidazóis/uso terapêutico , Nitroimidazóis/efeitos adversos , Estudos Observacionais como Assunto , Recém-Nascido , Adulto , Trypanosoma cruzi/efeitos dos fármacos , Complicações Parasitárias na Gravidez/prevenção & controle , Complicações Parasitárias na Gravidez/tratamento farmacológicoRESUMO
OBJECTIVE: Several studies point to antibacterial properties and beneficial effects of honey on scar tissue formation, which is a low-cost and easy-to-use option. This study aimed to compare honey versus a placebo for cicatrization and pain control of obstetric wounds, and determine if one is superior to the other, in terms of efficacy, through a meta-analysis. METHODS: We searched PubMed, Scopus, Cochrane Central Register of Controlled Trials, and Web of Science. Two independent investigators identified randomized controlled trials (RCTs) comparing honey and a placebo for obstetric wounds. The primary outcomes were wound healing and pain control. RESULTS: Five randomized controlled trials and 353 patients were included, of whom, 177 (50.1%) were treated with honey. Differences were not found in the final wound healing between the honey and placebo groups (MD -0.34; 95% CI -1.13, 0.44; p = 0.39); however, there was a decrease in pain levels in the middle of the treatment (SMD -0.54; 95% CI 0.83 to 0.25, p = 0.03), reduction in the use of pain medication (ORR 0.26; 95% CI 0.08, 0.86; p = 0.03), increase in personal satisfaction in women who underwent the intervention (ORR 0.81; 95% CI 0.65, 0.98), and reduction in complications. CONCLUSION: According to the study results, honey treatments showed greater efficiency and provided benefits to the patients by accelerating wound healing and decreasing reported pain.
Assuntos
Cicatriz , Mel , Feminino , Gravidez , Humanos , Ensaios Clínicos Controlados Aleatórios como Assunto , Manejo da Dor , Dor/etiologiaRESUMO
ABSTRACT This study aimed to evaluate the social and professional profile and knowledge of Primary Care professionals on maternal and child health. Cross-sectional descriptive study, from May to July 2018. It included 30 nurses and 73 Community Health Workers (CHW) from the municipality of Bragança, Pará. The form had three phases: participants' profile; close-ended questions on their profile, knowledge and resourcefulness on the First Week of Integral Care guideline; and four open-ended questions. Quantitative data was analyzed through Microsoft Office ExcelTM 2016, as qualitative data was arranged through word clouds and similarity trees in IRaMuTeQTM. The majority of nurses and CHW were female (70.9%) and worked in urban areas (60.2%), as 40% of nurses were graduated recently, with an 80% specialization courses, and 83.6% CHW had completed high school. On both categories, 82.5% did not know the First Week of Integral Health guideline, although the word clouds and similarity trees had shown that several national standardized orientations were provided. First Week of Integral Care guidelines' insufficient knowledge by nurses and CHW in the municipality points to fragility in Primary Care on maternal and child health. Although basic orientations are provided, improvement is necessary.
RESUMO Este estudo buscou avaliar o perfil socioprofissional e o conhecimento de profissionais da atenção primária sobre saúde materno-infantil. É um estudo transversal descritivo, realizado de maio a julho de 2018. Incluiu 30 enfermeiros e 73 Agentes Comunitários de Saúde (ACS) do município de Bragança, Pará. O formulário possuiu três fases: perfil dos participantes; perguntas fechadas sobre perfil, conhecimento e habilidade sobre a diretriz Primeira Semana de Saúde Integral; e quatro perguntas abertas. Os dados quantitativos foram analisados por meio do Microsoft Office ExcelTM 2016, enquanto os dados qualitativos foram organizados por meio de nuvens de palavras e árvores de similaridades no IRaMuTeQTM. A maioria dos enfermeiros e ACS eram mulheres (70.9%) e trabalhavam em áreas urbanas, enquanto 40% dos enfermeiros formaram-se recentemente, sendo 80% por cursos de especialização; 83% dos ACS possuíam ensino médio completo. Em ambas as categorias, 82.5% não conheciam a diretriz da Primeira Semana de Saúde Integral, embora as nuvens de palavras e as árvores de similaridade tenham mostrado que várias orientações padronizadas nacionalmente eram fornecidas. O conhecimento insuficiente da diretriz Primeira Semana de Saúde Integral por parte dos ACS e enfermeiros do município indica a fragilidade da atenção básica na saúde materno-infantil. Ainda que sejam fornecidas orientações básicas, há necessidade de melhora na qualidade do serviço.
RESUMO
BACKGROUND: Little is known about the evolution of peripheral arterial disease (PAD) since diagnosis and its association with glycemic and lipid control in patients with Type 2 Diabetes Mellitus (T2DM). OBJECTIVE: Evaluate the actual criteria to start screening PAD with ankle-brachial index (ABI) in T2DM patients and assess its progression and relationship with glycemic and lipid control since diagnosis. METHODS: We performed a 3-year prospective cohort study with two groups: group 1 (978 individuals with T2DM undergoing drug treatment) and group 2 [221 newly diagnosed drug-naive (< 3 months) patients with T2DM]. PAD diagnosis was by ABI ≤ 0.90, regardless any symptoms. RESULTS: As expected, abnormal ABI prevalence was higher in group 1 vs. Group 2 (87% vs. 60%, p < 0.001). However, abnormal ABI prevalence did not differ between patients over and under 50 years in both groups. Our drug-naive group stabilizes ABI (0.9 ± 0.1 vs 0.9 ± 0.1, p = NS) and improved glycemic and lipid control during follow-up [glycated hemoglobin (HbA1c) = 8.9 ± 2.1 vs 8.4 ± 2.3%, p < 0.05; LDL = 132 ± 45 vs 113 ± 38 mg/dL, p < 0.01, respectively]. When compared, patients who evolved with normalization or maintained normal ABI levels at the end [Group A, N = 60 (42%)] with those who decreased ABI to abnormal levels (ABI basal 1.0 ± 0.1 vs final 0.85 ± 0.1, p < 0.001) [Group B, N = 26 (18%)], an improvement in HbA1c (9 ± 2 vs 8 ± 2%, p < 0.05) and a correlation between the final HbA1c with ABI (r = - 0.3, p = 0.01) was found only in the first. In addition, a correlation was found between albuminuria variation and ABI solely in group A (r = - 0.3; p < 0.05). CONCLUSION: Our study suggests that ABI should be measured at diagnosis in T2DM patients, indicating that current criteria to select patients to screen PAD with ABI must be simplified. An improvement in albuminuria and glycemic and lipid control could be related with ABI normalization in newly diagnosed T2DM drug-naive patients.
Assuntos
Diabetes Mellitus Tipo 2 , Doença Arterial Periférica , Albuminúria , Índice Tornozelo-Braço , Glicemia , Estudos de Coortes , Diabetes Mellitus Tipo 2/diagnóstico , Diabetes Mellitus Tipo 2/tratamento farmacológico , Diabetes Mellitus Tipo 2/epidemiologia , Hemoglobinas Glicadas , Humanos , Lipídeos , Doença Arterial Periférica/diagnóstico , Doença Arterial Periférica/epidemiologia , Estudos Prospectivos , Fatores de RiscoRESUMO
BACKGROUND: Type 1 Diabetes Mellitus (T1DM) impacts health-related quality of life (HRQoL). Cross-sectional studies suggest that low levels of vitamin D (VD) may impair HRQoL, however, the effect of VD supplementation on quality of life in T1DM patients has not yet been clarified. Our study evaluated the effects of high-dose VD supplementation on HRQoL in T1DM. METHODS: We performed a prospective study with 64 patients receiving cholecalciferol (4000 IU/day for patients with 25-OH-vitamin D [25(OH)D] between 30 and 60 ng/mL, and 10,000 IU/day for those with 25(OH)D below 30 ng/mL) for 12 weeks, as part of a research protocol. HRQoL was assessed with EuroQol instruments (EQ-5D and EQ-VAS). RESULTS: There was an improvement in global EQ-5D index, and analysing specifically the EQ-5D domains, we observed an improvement in mobility (1.3 ± 0.6 versus 1.1 ± 0.3, p < 0.01). Evaluating possible outcome influencing variables, we detected a reduction in albuminuria at the end of the trial, without changes in BMI, lipids, blood pressure, glycemic control and insulin doses. We found correlations between final albuminuria and the dimensions: mobility (r = 0.6; p < 0.01), personal care (r = 0.7; p < 0.01), pain and discomfort (r = 0.6; p < 0.01) and habitual activities (r = 0.6; p < 0.01), suggesting an association between albuminuria reduction and the impact of VD supplementation on HRQoL. CONCLUSION: Our data showed that high doses of cholecalciferol supplementation can improve HRQoL in patients with T1DM, and the reduction of albuminuria seems to be an important factor in this context. TRIAL REGISTRATION: (ISRCTN32601947), 03/06/2017 retrospectively registered.